ImmuCell Co. (NASDAQ:ICCC) was the target of a large increase in short interest in the month of August. As of August 15th, there was short interest totalling 2,000 shares, an increase of 33.3% from the July 15th total of 1,500 shares. Based on an average trading volume of 6,800 shares, the short-interest ratio is presently 0.3 days. Currently, 0.1% of the company’s shares are short sold.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Ingalls & Snyder LLC raised its holdings in ImmuCell by 5.2% in the 2nd quarter. Ingalls & Snyder LLC now owns 96,243 shares of the biotechnology company’s stock valued at $626,000 after buying an additional 4,732 shares during the period. Eidelman Virant Capital purchased a new stake in ImmuCell in the 2nd quarter valued at about $91,000. Finally, Vanguard Group Inc. raised its holdings in ImmuCell by 20.3% in the 2nd quarter. Vanguard Group Inc. now owns 93,954 shares of the biotechnology company’s stock valued at $611,000 after buying an additional 15,885 shares during the period. Institutional investors and hedge funds own 23.62% of the company’s stock.
Shares of NASDAQ ICCC traded down $0.05 during trading on Tuesday, hitting $5.70. 1,549 shares of the company were exchanged, compared to its average volume of 3,326. ImmuCell has a 12-month low of $5.30 and a 12-month high of $9.30. The company has a quick ratio of 6.76, a current ratio of 8.22 and a debt-to-equity ratio of 0.27. The company has a fifty day moving average price of $6.03 and a 200-day moving average price of $6.43.
ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E.
Read More: What is a front-end load?
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.